Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130722 · ClinicalTrials.gov registry record · Phase 1
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
A Phase 1 study of Locally Advanced/Metastatic Solid Tumors, sponsored by Suzhou Forlong Biotechnology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT06130722 is a Phase 1 study of Locally Advanced/Metastatic Solid Tumors that has completed, run by Suzhou Forlong Biotechnology Co.. The registered enrollment target is 18 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT06130722, a Phase 1 study of Locally Advanced/Metastatic Solid Tumors, has completed, sponsored by Suzhou Forlong Biotechnology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.
Conditions Studied
Interventions
- DRUG FL115
Study Locations (3)
California
- HOAG Memorial Hospital Presbyterian - Newport Beach
- Moores Cancer Center at UCSD Health - San Diego
Ohio
- Gabriel Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-12-30 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06130722
The ClinicalTrials.gov registry entry for NCT06130722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Forlong Biotechnology Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced/Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which FL115 is the first listed.
NCT06130722 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06130722 about?
NCT06130722 is a clinical study titled "First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study". First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, includin...
What is the current status of trial NCT06130722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-12-30. Estimated completion is 2025-09-19.
What conditions does trial NCT06130722 study?
This clinical trial studies the following conditions: Locally Advanced/Metastatic Solid Tumors.
What interventions are being tested in trial NCT06130722?
The interventions under investigation include: FL115 (DRUG).
Who is sponsoring clinical trial NCT06130722?
This trial is sponsored by Suzhou Forlong Biotechnology Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06130722 being conducted?
This trial has 3 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced/Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.